Evidence map›Paper›PMID 41918846›Full record

SynthesisInternational journal of nanomedicine2026

Nanomaterial-Based Precision Drug Delivery for Advanced Nephrology Therapy: A Systematic Review.

Jiayi Feng, Rongrong Zhang, Xu Chen, Meng Jia, Liang Li, Lu Zhang, Yi Fu

Abstract readSystematic Review
In one paragraph

Synthesis in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiayi Feng *Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Rongrong Zhang *Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Xu ChenDepartment of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Meng JiaDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Liang LiDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lu ZhangDepartment of Cardiology, Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, Fujian, People's Republic of China.
Yi FuDepartment of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, People's Republic of China.ORCID 0000-0003-1773-007X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney disease represents a serious global health challenge. Current therapeutic strategies often lack the precision to deliver drugs specifically to the kidneys, potentially leading to systemic side effects. Nanomaterials offer a promising alternative, as their size and surface properties can be engineered to facilitate renal accumulation and retention. This systematic review summarizes recent advances in four primary nanomaterial platforms for nephrology therapy, namely lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, and exosome delivery system. It focuses on how these rationally designed nanomaterials overcome inherent physiological barriers of the kidney (eg, the glomerular filtration barrier) and how their surface modification with targeting ligands enables response to pathological microenvironments to achieve controlled drug release. Furthermore, the theranostic potential of nanomaterials in kidney disease diagnosis, such as in advanced imaging and disease monitoring, is also discussed. Finally, this review identifies key challenges to the clinical translation of renal nanomedicines, including biosafety, limitations of murine models, insufficient long-term safety, suboptimal targeting accuracy, and scalable manufacturing hurdles, and suggests potential strategies to facilitate their bench-to-bedside translation and improve kidney disease management. In conclusion, this review provides a comprehensive overview of nanomaterial applications in nephrology, clarifying their potential and challenges to lay a foundation for promoting clinical translation and improving kidney disease care.

Indexed as

Kidney DiseasesNanoparticle Drug Delivery SystemNanoparticlesAnimalsHumansKidneyNanomedicineNephrologyPrecision MedicineNanoparticle Drug Delivery Systemdrug delivery systemskidney diseasenanomaterials

Identifiers

PMID41918846
PMCPMC13033420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.